News & Events

News


Thursday October 05, 2017

Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)

First and only TD therapy taken as one capsule, once per day; new 80 mg capsule expected to be available for patients within two weeks INBRACE™ program offers patients access to treatment and patient assistance SAN DIEGO, Oct. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved an 80 mg INGREZZA® (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which was approved by the FDA April 11, 2017, is the first FDA-approved product indicated for the treatment of adults wit...


Friday September 15, 2017

Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress

SAN DIEGO, Sept. 15, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced today upcoming poster presentations at the 2017 Annual Psych Congress featuring data from the RE-KINECT study outlining the real-world presence and impact of tardive dyskinesia (TD) on the lives of both patients and caregivers. Neurocrine will also present four posters regarding INGREZZA® (valbenazine) capsules, the first FDA-approved treatment for adults with tardive dyskinesia, including data on the effects of INGREZZA on tardive dyskinesia (TD) in different body regions and the safety profile of INGREZZA with respect to metabolic parameters. "This year's Psych Congress serves as an excellent...


Wednesday September 06, 2017

Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

Live Audio Webcast Will be on September 11, 2017 SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference in New York City. The live presentation takes place on Monday, September 11 at 11:05am ET (8:05am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on ...


Wednesday August 30, 2017

Neurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference

Live Audio Webcast Will be on September 6, 2017 SAN DIEGO, Aug. 30, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Baird 2017 Global Healthcare Conference in New York City. The live presentation takes place on Wednesday, September 6 at 2:35pm ET (11:35am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website app...


Thursday August 03, 2017

Neurocrine Biosciences Reports Second Quarter 2017 Results

- INGREZZA® Net Product Sales of $6.3 Million in Initial Two Months of Commercialization as the First and Only U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia - Partner AbbVie Expected to Submit Elagolix NDA for Endometriosis During the Third Quarter of 2017 and Pay $30 Million Milestone in Fourth Quarter of 2017 - Partner Mitsubishi Tanabe Expected to Initiate Pivotal Trial of INGREZZA in Asia for the Treatment of Tardive Dyskinesia and Pay $15 Million in Milestones during Third Quarter of 2017 - Completed Offering of $517.5 Million Convertible Senior Notes Due 2024 SAN DIEGO, Aug. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASD...

Events